Arrhythmogenic right ventricular dysplasia

source: shutterstock.com

Sudden Arrhythmia Death Syndromes Foundation (SADS) Educates FDA on Living with ARVC/D Through Externally-Led Patient-Focused Drug Development Meeting

Post author:Patient Worthy Contributor
Post published:August 24, 2023
Post category:Arrhythmogenic right ventricular dysplasia Sudden Arrhythmia Death Syndrome

This press release was provided by the Sudden Arrhythmia Death Syndrome Foundation (SADS), a Patient Worthy partner organization. Key facts: ● Externally-led patient-focused drug development meeting (EL-PFDD) with FDA hosted…

source: pixabay.com

RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

Post author:Jessica Lynn
Post published:June 20, 2023
Post category:Arrhythmogenic right ventricular dysplasia PKP2 arrhythmogenic cardiomyopathy

Gene therapy has the potential to improve outcomes among individuals across various disease spectrums. In the case of clinical-stage biotechnology company Rocket Pharmaceuticals, the company is working to develop…

Get Involved

Sudden Arrhythmia Death Syndromes Foundation (SADS) Educates FDA on Living with ARVC/D Through Externally-Led Patient-Focused Drug Development Meeting

RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More